Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: A critical review of published articles from 1970 to 2009

Osteoporosis International

Volumn 22, Issue 3, 2011, Pages 741-753

  Lee, S ^a   Glendenning, P ^b,c   Inderjeeth, C A ^a,b,d  

^a North Metropolitan Area Health Service   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Adherence; Compliance; Medication; Osteoporosis; Persistence; Preference

Indexed keywords

ALENDRONIC ACID; CALCITONIN; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT PREFERENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNSPECIFIED SIDE EFFECT;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79951682540     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1335-x     Document Type: Review

References (67)

1. KW Lyles CS Colon-Emeric JS Magaziner, et al. 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 1:CAS:528:DC%2BD2sXht1Kit7nN 10.1056/NEJMoa074941 17878149 (Pubitemid 350044800)
2. World Health Organisation (2003) Adherence to long-term therapies. Evidence for action 2003. Available at www.who.int/chp/knowledge/publications/ adherence-report/en/
3. Kinsella K, Velkoff V (2001) An aging world 2001. International population reports. Available at http://www.census.gov/prod/2001pubs/p95-01-1. pdf
4. Haynes RB, McDonald H, Garg AX, Montague P (2002) Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev CD000011
5. JT Harrington LG Ste-Marie ML Brandi, et al. 2004 Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Calcif Tissue Int 74 129 135 1:CAS:528:DC%2BD2cXhtFGjt78%3D 10.1007/s00223-003-0042-4 14648009 (Pubitemid 38263854)
6. ST Harris NB Watts HK Genant, et al. 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352 1:CAS:528:DyaK1MXmvFansr0%3D 10.1001/jama.282.14.1344 10527181 (Pubitemid 29483192)
7. S Adami D Felsenberg C Christiansen, et al. 2004 Efficacy and safety of ibandronate given by intravenous injection once every 3 months Bone 34 881 889 1:CAS:528:DC%2BD2cXjs1Wktrk%3D 10.1016/j.bone.2004.01.007 15121020 (Pubitemid 38581134)
8. PD Delmas RR Recker CH Chesnut 3rd, et al. 2004 Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study Osteoporos Int 15 792 798 1:CAS:528:DC%2BD2cXnsVCit7g%3D 10.1007/s00198-004-1602-9 15071723 (Pubitemid 39361949)
9. IR Reid JP Brown P Burckhardt, et al. 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density N Engl J Med 346 653 661 1:CAS:528:DC%2BD38XhsFOjsrw%3D 10.1056/NEJMoa011807 11870242 (Pubitemid 34815869)
10. DM Black PD Delmas R Eastell, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 1:CAS:528:DC%2BD2sXltVSktLc%3D 10.1056/NEJMoa067312 17476007 (Pubitemid 46698462)
11. JR Tucci RP Tonino RD Emkey CA Peverly U Kher AC Santora 2nd 1996 Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis Am J Med 101 488 501 1:CAS:528:DyaK28XnsFOmsrg%3D 10.1016/S0002-9343(96)00282-3 8948272 (Pubitemid 126335969)
12. B Ettinger DM Black BH Mitlak, et al. 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 637 645 1:CAS:528: DyaK1MXlvVKqurg%3D 10.1001/jama.282.7.637 10517716 (Pubitemid 29384151)
13. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev CD005326
14. CA Inderjeeth AC Foo MM Lai P Glendenning 2009 Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence Bone 44 744 751 1:CAS:528:DC%2BD1MXktFags7Y%3D 10.1016/j.bone.2008.12. 003 19130909
15. Haynes RB (1979) Determinants of compliance: the disease and the mechanics of treatment. In: Haynes RB, Taylor DW, Sackett DL (eds) Compliance in health care. Johns Hopkins University Press, Baltimore, pp 49-62
16. CS Rand 1993 Measuring adherence with therapy for chronic diseases: implications for the treatment of heterozygous familial hypercholesterolemia Am J Cardiol 72 68D 74D 1:STN:280:DyaK2c%2Fis1Oitg%3D%3D 10.1016/0002-9149(93) 90014-4 8213501 (Pubitemid 23286506)
17. A Papaioannou CC Kennedy L Dolovich E Lau JD Adachi 2007 Patient adherence to osteoporosis medications: problems, consequences and management strategies Drugs Aging 24 37 55 1:CAS:528:DC%2BD2sXjt1Kht7w%3D 10.2165/00002512-200724010-00003 17233546 (Pubitemid 46148080)
18. V Rabenda R Mertens V Fabri, et al. 2008 Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women Osteoporos Int 19 811 818 1:CAS:528:DC%2BD1cXltFyjurs%3D 10.1007/s00198-007-0506-x 17999022
19. Compston J (2003) Do we need to monitor anti-osteoporosis treatement anyway? In: 30th European Symposium on Calcified Tissues. Rome, Italy
20. J Reginster HW Minne OH Sorensen, et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 83 91 1:CAS:528:DC%2BD3cXhvFGgsr0%3D 10.1007/s001980050010 10663363 (Pubitemid 30099515)
21. DM Black SR Cummings DB Karpf, et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541 1:CAS:528:DyaK2sXisFCktQ%3D%3D 10.1016/S0140-6736(96)07088-2 8950879 (Pubitemid 26411651)
22. UA Liberman SR Weiss J Broll, et al. 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N Engl J Med 333 1437 1443 1:CAS:528:DyaK28XkslehtA%3D%3D 10.1056/ NEJM199511303332201 7477143
23. AY Ho AW Kung 2005 Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women Ann Pharmacother 39 1428 1433 1:CAS:528:DC%2BD2MXhtVWjtrvL 10.1345/aph.1E580 16076919 (Pubitemid 41197121)
24. B Ettinger A Pressman J Schein J Chan P Silver N Connolly 1998 Alendronate use among 814 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation J Manag Care Pharm 4 488 492
25. RA Yood S Emani JI Reed BE Lewis M Charpentier E Lydick 2003 Compliance with pharmacologic therapy for osteoporosis Osteoporos Int 14 965 968 1:CAS:528:DC%2BD3sXpvVCms74%3D 10.1007/s00198-003-1502-4 14504697 (Pubitemid 40824268)
26. JS McCombs P Thiebaud C McLaughlin-Miley J Shi 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271 287 1:CAS:528:DC%2BD2cXltVCiu7g%3D 10.1016/j.maturitas.2004.02.005 15207894 (Pubitemid 38781153)
27. ES Siris ST Harris CJ Rosen, et al. 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022 10.4065/81.8.1013 16901023 (Pubitemid 44175011)
28. FJ Penning-van Beest WG Goettsch JA Erkens 2004 Persistence with bisphosphonate therapy among post-menopausal osteoporotic women and the impact of dosing frequency Value Health 7 724
29. W Cowell A Fulford-Smith S Poultney 2005 Adherence with bisphosphonate treatment for osteoporosis in UK patients Bone 36 Suppl 2 S409 S410
30. Harris ST, Siris ES, Abbott TA, Barr CE, Rosen CJ (2005) Reduced osteoporotic fracture risk in patients adherence to bisphosphonate therapy. In: Program & Abstracts of The Endocrine Society's 87th Annual Meeting; 2005 4-7 June, p 3-382
31. JY Reginster V Rabenda 2006 Patient preference in the management of postmenopausal osteoporosis with bisphosphonates Clin Interv Aging 1 415 423 1:CAS:528:DC%2BD2sXjt1Gqs7k%3D 10.2147/ciia.2006.1.4.415 18046918
32. International Osteoporosis Foundation (2005) IOF adherence report [online]. Available at http://www.osteofound.org/publications/pdf/adherence-gap- report.pdf
33. AJ Claxton J Cramer C Pierce 2001 A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 1296 1310 1:STN:280:DC%2BD3MrhtVKktA%3D%3D 10.1016/S0149-2918(01)80109-0 11558866 (Pubitemid 32804122)
34. A Richter SE Anton P Koch SL Dennett 2003 The impact of reducing dose frequency on health outcomes Clin Ther 25 2307 2335 10.1016/S0149-2918(03)80222- 9 14512137 discussion 6 (Pubitemid 37076322)
35. JA Simon EM Lewiecki ME Smith RA Petruschke L Wang JJ Palmisano 2002 Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study Clin Ther 24 1871 1886 1:CAS:528:DC%2BD38Xpsleku7w%3D 10.1016/S0149-2918(02)80085-6 12501880 (Pubitemid 35440956)
36. D Kendler AW Kung H Fuleihan Gel, et al. 2004 Patients with osteoporosis prefer once weekly to once daily dosing with alendronate Maturitas 48 243 251 1:CAS:528:DC%2BD2cXltVCiu7o%3D 10.1016/j.maturitas.2003.12.012 15207890 (Pubitemid 38781149)
37. B Baroutsou D Babiolakis AE Stamatiadou, et al. 2004 Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women Ann Rheum Dis 63 Supple 1 455
38. M Weiss I Vered AJ Foldes YC Cohen Y Shamir-Elron S Ish-Shalom 2005 Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study Aging Clin Exp Res 17 143 149 1:CAS:528:DC%2BD2MXls1altLY%3D 15977463 (Pubitemid 41558123)
39. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460 1:CAS:528:DC%2BD2MXhtFKqu7zP 10.1185/030079905X61875 16197664 (Pubitemid 41368578)
40. RR Recker R Gallagher PE MacCosbe 2005 Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women Mayo Clin Proc 80 856 861 10.4065/80.7.856 16007889 (Pubitemid 40911458)
41. J Sunyecz R Gallagher PE MacCosbe 2006 Persistence with medication in women taking daily versus weekly bisphosphonates for osteoporosis Female Patient 31 21 28
42. MP Ettinger R Gallagher PE MacCosbe 2006 Medication persistence with weekly versus daily doses of orally administered bisphosphonates Endocr Pract 12 522 528 17002926 (Pubitemid 46456039)
43. E Brankin M Walker N Lynch T Aspray Y Lis W Cowell 2006 The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases Curr Med Res Opin 22 1249 1256 1:CAS:528:DC%2BD28XotlKgtLw%3D 10.1185/030079906X112688 16834823 (Pubitemid 44085576)
44. SL Silverman DT Gold 2008 Compliance and persistence with osteoporosis therapies Curr Rheumatol Rep 10 118 122 10.1007/s11926-008-0021-x 18460266
45. TW Weiss CA McHorney 2007 Osteoporosis medication profile preference: results from the PREFER-US study Health Expect 10 211 223 10.1111/j.1369-7625. 2007.00440.x 17678510 (Pubitemid 47196352)
46. TW Weiss DT Gold SL Silverman CA McHorney 2006 An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study Curr Med Res Opin 22 949 960 10.1185/030079906X104740 16709316 (Pubitemid 43875562)
47. JW Duarte SC Bolge SS Sen 2007 An evaluation of patients' preferences for osteoporosis medications and their attributes: the PREFER-International study Clin Ther 29 488 503 10.1016/S0149-2918(07)80087-7 17577470 (Pubitemid 46915454)
48. DT Gold W Safi H Trinh 2006 Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate Curr Med Res Opin 22 2383 2391 1:CAS:528:DC%2BD2sXhsVOlt7k%3D 10.1185/030079906X154042 17257452 (Pubitemid 46055201)
49. JA Simon K Beusterien A Hebborn LN Kline 2005 Bisphosphonate dosing preferences in women with postmenopausal osteoporosis: a study Female Patient 30 31 36
50. R Emkey W Koltun K Beusterien, et al. 2005 Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO) Curr Med Res Opin 21 1895 1903 1:CAS:528:DC%2BD28XhtF2juro%3D 10.1185/030079905X74862 16368038 (Pubitemid 41803098)
51. P Hadji H Minne M Pfeifer, et al. 2008 Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II) Joint Bone Spine 75 303 310 1:CAS:528:DC%2BD1cXnsFWkt7w%3D 10.1016/j.jbspin.2007.07.011 18069036
52. TW Weiss SC Henderson CA McHorney JA Cramer 2007 Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills Curr Med Res Opin 23 2193 2203 10.1185/030079907X226069 17686228 (Pubitemid 350246605)
53. Silverman S, Cramer J, Sunyecz J et al (2007) Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12-month results from two retrospective databases [abstract W366]. In: 29th Annual Meeting of the American Society for Bone and Mineral Research; 2007 Sept 16-20; Honolulu, HI
54. A Cooper J Drake J Drake E Brankin 2006 Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study Int J Clin Pract 60 896 905 1:CAS:528: DC%2BD28XpvVemsLg%3D 10.1111/j.1742-1241.2006.01059.x 16800837 (Pubitemid 44082279)
55. A Cooper 2006 Compliance with treatment for osteoporosis Lancet 368 1648 10.1016/S0140-6736(06)69691-8 17098078 (Pubitemid 46055219)
56. JB Richards LF Cherkas TD Spector 2007 An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults Curr Med Res Opin 23 293 299 1:STN:280: DC%2BD2s%2FptFaksQ%3D%3D 10.1185/030079906X162764 17288683 (Pubitemid 46333377)
57. RA Yood KM Mazor SE Andrade S Emani W Chan KH Kahler 2008 Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs J Gen Intern Med 23 1815 1821 10.1007/s11606-008-0772-0 18787907
58. M McClung R Recker P Miller, et al. 2007 Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate Bone 41 122 128 1:CAS:528:DC%2BD2sXmsFKkurc%3D 10.1016/j.bone.2007.03.011 17468062 (Pubitemid 46901056)
59. K Saag R Lindsay A Kriegman E Beamer W Zhou 2007 A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density Bone 40 1238 1243 1:CAS:528:DC%2BD2sXktF2nsrg%3D 10.1016/j.bone.2007.01.016 17347063 (Pubitemid 46550991)
60. L Fraenkel B Gulanski D Wittink 2006 Patient treatment preferences for osteoporosis Arthritis Rheum 55 729 735 10.1002/art.22229 17013870 (Pubitemid 44619186)
61. DL Kendler L Bessette CD Hill, et al. 2009 Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass Osteoporos Int 21 837 846 10.1007/s00198-009-1023-x 19657689
62. P Kothawala E Badamgarav S Ryu RM Miller RJ Halbert 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1493 1501 10.4065/82.12.1493 18053457 (Pubitemid 350211697)
63. RD Jackson AZ LaCroix M Gass, et al. 2006 Calcium plus vitamin D supplementation and the risk of fractures N Engl J Med 354 669 683 1:CAS:528:DC%2BD28XhsVWksr0%3D 10.1056/NEJMoa055218 16481635 (Pubitemid 43247138)
64. AM Grant A Avenell MK Campbell, et al. 2005 Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial Lancet 365 1621 1628 1:STN:280:DC%2BD2M3kslClsA%3D%3D 10.1016/S0140- 6736(05)63013-9 15885294 (Pubitemid 40693411)
65. JY Reginster V Rabenda A Neuprez 2006 Adherence, patient preference and dosing frequency: understanding the relationship Bone 38 S2 S6 1:STN:280:DC%2BD287mvFOitA%3D%3D 10.1016/j.bone.2006.01.150 16520104
66. CA Inderjeeth D Glennon A Petta 2006 Study of osteoporosis awareness, investigation and treatment of patients discharged from a tertiary public teaching hospital Intern Med J 36 547 551 1:STN:280:DC%2BD28voslOitg%3D%3D 10.1111/j.1445-5994.2006.01146.x 16911544 (Pubitemid 44179828)
67. Access Economics Pty Ltd (2010) A future less fragile. Available online at http://www.accesseconomics.com.au/publicationsreports